• Edit
DateInvestorsAmountRound
-

N/A

-
Total Funding-

Recent News about CellCarta

Edit
More about CellCarta
Edit

Founded in 2000, Caprion Biosciences is a specialty CRO laboratory with world-renowned expertise in immune monitoring, proteomics and biomarker research. With an unwavering commitment to proactive scientific collaboration and service excellence, combined to the highest quality standards, we truly believe we can change the world of precision medicine. Caprion recently united with HistoGeneX, a leading provider of immuno-oncology tissue pathology and genomics biomarker assessment services. The combined entities have nine laboratory facilities globally located in Canada, the United States, Belgium, UK, Australia, and China. Caprion and HistoGeneX are privately held and majority-owned by Arsenal Capital Partners. Our state-of-the-art facilities are GLP, GCLP, CAP and/or CLIA accredited. Our locations include: Caprion Biosciences: Montreal, Quebec; Gosselies, Belgium HistoGeneX: Antwerp, Belgium; Chicago, Illinois; Jining, China Serametrix: Carlsbad, California; Guildford, United Kingdom; Sydney, Australia Primity Bio: Fremont, California

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by CellCarta

Edit
Biogazelle
ACQUISITION by CellCarta Dec 2021
Reveal Biosciences
ACQUISITION by CellCarta May 2021
Clinical Logistics
ACQUISITION by HistoGeneX Jan 2021